中国国际医疗器械设计与制造技术展览会(Medtec China)2021

专注于为医疗器械研发与生产服务

2022年8月31-9月2日 | 上海世博展览馆1&2号馆

Perfecting the Future of Data-Driven Healthcare

2021-12-09

Data-driven patient care is undoubtedly the future of the healthcare field. Automation opens the door to improved efficiencies, more personalized care, and improved profitability, but in healthcare, the implementation and advancement of these technologies are not without challenges unique to medicine.

Data-driven patient care is undoubtedly the future of the healthcare field. Automation opens the door to improved efficiencies, more personalized care, and improved profitability, but in healthcare, the implementation and advancement of these technologies are not without challenges unique to medicine.

Healthcare data is not only highly variable and complex but is extremely sensitive. Given the regulated nature of healthcare data and patient information, mistakes can compromise HIPAA compliance, and even more severe, mismanaged data can potentially result in life or death results.

However, the promise of these technologies is enormous. A few years ago, John Hopkins conducted a study establishing medical error as the third-leading cause of death in the United States. The maturation of AI and ML tools will help doctors identify complications before their life or death and ultimately improve patient outcomes.

Patrick Bangert, VP of AI at Samsung SDSA, is set to address the key risks and opportunities that automation technologies pose in the healthcare space in a keynote panel at the upcoming BIOMEDevice Silicon Valley Smart Event, titled “The Three Magic Words for Healthcare - Artificial Intelligence, Big Data & Edge Computing.” The premiere exhibition, slated to take place December 8 and 9 at the San Jose McEnery Convention Center, is strategically designed to connect biotech and medtech engineers and cutting-edge companies and provide world-class education both in-person and online.

With the event on the near horizon, I had the distinct pleasure of sitting down with Patrick and discussing the keynote panel and what attendees can look forward to learning.

AI and ML capabilities are driving the smarter delivery of more efficient and precise products. What notable trends are emerging as a result of integrating AI/ML capabilities with healthcare?
Bangert: Automation is the primary benefit of AI in any industry. AI frees up doctors and other healthcare professionals to focus on the patient where momentarily they are spending 75% of their time analyzing data and doing paperwork. Patients have to wait 4-6 weeks, unaware of the results of a biopsy. If those are available instantly, the treatment can begin sooner, leading to better outcomes. The most significant benefit will be felt in those regions that don’t have A-rated facilities. On average, 30% of human diagnoses are mistaken, while AI can be accurate to over 99%. AI can democratize healthcare worldwide.

Ongoing technological advances open the door for medical breakthroughs but also incite new obstacles. Could you speak to these challenges? Bangert: Regulation is a major obstacle, particularly because the regulation is different in every country. Trust is a worldwide obstacle to AI adoption in many areas, and we have much work ahead to have the population at large trust an automated system with their health. For the technology sector, the main obstacle, however, is quality data. The data must be acquired and annotated by human experts, which is the main cost of AI. We at Samsung SDS are reducing this work by 90% with AI automation.

How do you see today’s data-driven approach to research and device development impacting healthcare delivery in the future?
Bangert: This will speed up the industry by leaps and bounds and reduce research costs significantly. We can expect to see progress at a faster pace and also updates in hospitals faster than before.

You are speaking on a keynote panel with three peers at BIOMEDevice Silicon Valley. What can attendees look forward to learning?
Bangert: A key frontier for AI is medical devices. The frontier for medical devices is AI. The industry has been improving medical devices little by little over many years. There is little breakthrough or game-changing innovation. AI offers a bold new vision where the medical device is the first step as a sensor to the world, but it is the analysis of the acquired data that presents the value – both to the industry as well as the patient.

What excites you most about engaging with your community in person this December?
Bangert: Meeting them in person, learning about new developments, and sharing ideas about how AI can help drive innovation and make devices as well as outcomes better.

Secure a pass here to tune into the keynote pane and engage with more than 200 suppliers advancing the integration of advanced technologies in healthcare. Access the online platform that is open today and begin earning points for the chance to win cash and high-tech prizes. The more education you tune into, the more points you earn!

Article source: Qmed and MD+DI

 

伴随着人工智能兴起,起步较晚的国产医疗机器人正在加快发展,逐步扩大应用场景。5月26日,第十一届中国生物产业大会在武汉光谷发布本土健康企业的7项最新成果,首先推介的便是武汉兰丁公司的宫颈癌检测智能机器人。

 

《每日经济新闻》记者在大会现场了解到,多家企业正在推广医疗机器人,应用范围涵盖胃镜检查、腹腔手术、美容抗衰等,并且已有成熟产品进入国内医院,打破进口机器人在医院应用的垄断局面。

 

 

据主办方介绍,“LANDING”机器人通过筛查样本拨片进行自动化诊断,每月有108万例的样本检测能力,效率远远超过人工。目前,武汉兰丁公司与阿里巴巴的合作,使“LANDING”机器人在中国各地基层终端收集的大量细胞特征参数及数据,在云平台上完成分析诊断工作。

 

 

科技颠覆想象力,机器人在医疗领域的应用范围更加广泛。《每日经济新闻》记者注意到,多家企业在生物产业大会上重点推介医疗机器人产品。

 

患者吞下一粒胶囊,在胃里变成机器人进行螺旋式扫描,将检查图像实时传输至医生电脑,这便是安翰光电技术(武汉)有限公司研制的磁控胶囊胃镜机器人。该公司展位负责人程先生介绍,目前全国已有1000多家医疗机构应用了胶囊胃镜机器人,包括三甲医院、大型体检中心等,涵盖专业医疗和常规健康体检领域,年消耗量达50万粒。

 

据了解,这粒胶囊仅重5G,但包含了80多项科技创新专利,集成400多个精密元器件。上述负责人表示,在检查方面,胃镜机器人可以替代传统的电子胃镜,不过电子胃镜可以做小型的腔镜手术、切片等,胶囊机器人还不具备这些功能,但在进一步研发中。

 

苏州康多机器人有限公司则在大会上重点推介腹腔镜手术机器人系统,该公司展位负责人张辉介绍,这款手术机器人由医生控制台、支撑臂、手术器械三部分组成,通过机器人操作可以起到防止手抖、放大病灶视野等精确治疗的效果。

 

其实,在“机器换人”升级过程中,国产医疗机器人起步虽晚,但发展很快,不少上市公司将其作为下一风口进行布局。

 

2015年,制造装备公司楚天科技(行情300358,诊股)(300358,SZ)表示正在研发医药机器人和医疗机器人,一年后,首台医药无菌生产智能机器人下线,步入医药装备4.0时代;2017年11月,科大讯飞(行情002230,诊股)(002230,SZ)研发的医疗机器人“智医助理”通过临床执业医师综合笔试,目前已进入合肥基层卫生中心,辅助全科医生进行诊疗;2017年,埃斯顿(行情002747,诊股)(002747,SZ)收购美国Barrett 30%股权,全面进军康复医疗机器人市场,并计划与Barrett共同出资在中国境内成立一家新的合公司。

 

国产机器人拥有成本优势 在多家企业布局的背后,是医疗机器人巨大的市场潜力。普华永道中国发布的《医疗机器人宏观应用趋势与研究方向》显示,2014年,全球医疗机器人的市场价值是26亿美元,到2020年预计会达到76亿美元。

 

人均可支配收入的增加会促使高质量医疗需求的增长,而医疗机器人正好有出血少、精准度更高,恢复快的优势。整个发展趋势显示医疗机器人市场潜力巨大。

 

目前,国内医院的医疗机器人仍依赖进口,最为广泛应用的就是美国直觉外科公司制造的达芬奇手术机器人,2016年国内手术量突破1.5万台。

 

但是,进口医疗机器人价格昂贵,使得医疗费用也居高不下,如一台达芬奇机器人在国内售价2000万元左右,附带长期的耗材费用。

 

“进口机器人就算不用,一年的保养费都得80~100万元,每天开机费用就达1万元左右。”张辉表示,国外的机器人设备,主要包括维修费、保养费、耗材费等费用,所以价格居高不下。

 

随着国产医疗机器人发力,这一局面有望打破。此前,楚天科技研发的医药无菌生产机器人定价500万~600万元,而国际同类机器人定价800万~1000万元左右。

 

张辉告诉《每日经济新闻》记者,国产医疗机器人的优势是小型化、便捷化,还有国内的服务体系,针对三甲医院、县级医院等机构,可以实现分级应用,因此价格应该会比进口设备低一半左右,降低医疗成本。

 

来源:每日经济新闻

返回新闻列表